Search research articles
Contact Us
Filters
Showing results (131-140 of 247) with videos related to
Page
of 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors
Jordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.
Cancer Research Communications
|
December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
The Oncologist
|
March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials
Ryan W Huey, Goldy C George, Penny Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2023
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers
Tin-Yun Tang, Federico Nichetti, Ben Kaplan, et al.
Journal of Neuro-Oncology
|
November 29, 2019
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Martin van den Bent, Analia Azaro, Filip De Vos, et al.
Scientific Reports
|
May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
Shuyang Yao, Funda Meric-Bernstam, David Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
Emerging Microbes & Infections
|
April 7, 2021
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
Marco Brustolin, Jordi Rodon, María Luisa Rodríguez de la Concepción, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodon, Josep Tabernero, et al.
Page
of 25
Search research articles
Search
Showing results (131-140 of 247) with videos related to
Sort By:
Page
of 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors
Jordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.
Cancer Research Communications
|
December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
The Oncologist
|
March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials
Ryan W Huey, Goldy C George, Penny Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2023
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers
Tin-Yun Tang, Federico Nichetti, Ben Kaplan, et al.
Journal of Neuro-Oncology
|
November 29, 2019
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Martin van den Bent, Analia Azaro, Filip De Vos, et al.
Scientific Reports
|
May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
Shuyang Yao, Funda Meric-Bernstam, David Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
Emerging Microbes & Infections
|
April 7, 2021
Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
Marco Brustolin, Jordi Rodon, María Luisa Rodríguez de la Concepción, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodon, Josep Tabernero, et al.
Page
of 25